learndrugs
Reproductive & OB

Gestational Diabetes

GDM High-yield Verified · Oct 2026

Gestational diabetes mellitus is diabetes that develops during pregnancy — usually around the 24th week — when the body cannot make the extra insulin it needs against the insulin resistance produced by placental hormones.

The disorder behind the 24-to-28-week screen, the one-step-versus-two-step argument, insulin-because-it-does-not-cross-the-placenta, the shoulder that will not deliver, and the newborn whose glucose falls the moment the cord is cut.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 The placenta causes it — and it is supposed to

Gestational diabetes "usually develops around the 24th week of pregnancy," and "It happens when your body can't make the extra insulin it needs during pregnancy" — and the organ responsible is the placenta. "Placental hormone release causes marked insulin resistance. Human placental lactogen is the primary hormone associated with increased insulin resistance." It does not act alone: "physiologic increases in circulating placental hormones, including growth hormone, corticotrophin-releasing hormone, human placental lactogen, prolactin, estrogen, and progesterone, increase insulin resistance during a normal pregnancy." Note the word physiologic. Insulin resistance in pregnancy is normal, expected and useful, because it diverts maternal glucose across the placenta to the fetus, where "glucose transfer through the placenta occurs through facilitated diffusion."

What makes it a disease is the failure to compensate. "Maternal pancreatic β-cell dysfunction resulting in decreased insulin secretion is the primary mechanism that results in the inability to control maternal insulin resistance." Put to a patient: the body cannot make the extra insulin that pregnancy demands of it. Every healthy pregnancy runs this resistance; GDM is the pregnancy in which the pancreas cannot outrun it. And because the driver is placental hormone output, and placental mass grows through gestation, the resistance and the insulin requirement climb through the third trimester — the dose that was right at 28 weeks is usually not the dose at 36 weeks.

That timing explains the whole diagnostic calendar. Physiologic resistance begins in the second trimester, so the screen sits at 24 to 28 weeks, and it also explains why GDM is not a cause of congenital anomalies. High glucose at the beginning of a pregnancy raises birth-defect risk, but by definition GDM develops in the second half — after organogenesis. GDM's fetal signature is overgrowth, not malformation. GDM sorts into two classes that are really two treatment plans: A1GDM is controlled with nutritional therapy alone, without medications, and A2GDM needs medication to reach glycemic control.

The Pedersen chain. One mechanism — glucose crosses the placenta and insulin does not — produces both the delivery emergency and the newborn emergency, which is why the same page teaches both.

02 The Pedersen chain — why the baby is big in a particular shape

The fetal half of this page hangs on one sentence, the Pedersen hypothesis of 1920 — that "maternal hyperglycemia is associated with fetal hyperinsulinemia" and fetal hyperglycemia, which in turn leads to overutilization of glucose by the fetus and an abnormal increase in growth. Note the operator: the hypothesis states an association, and a page that upgrades it to "causes" is quoting something the source does not say. Maternal glucose crosses the placenta freely; maternal insulin does not. The fetal pancreas therefore sees a glucose load it must answer itself, and it answers with "hyperplasia of the β-islet cells of the fetal pancreas, leading to overutilization of glucose by the fetus."

The growth that follows is driven by the fetus's own insulin: infants of diabetic mothers "commonly develop fetal hyperinsulinism and increased peripheral glucose utilization," and GDM raises the risk of "fetal macrosomia (which can cause shoulder dystocia and birth injury)." Shoulder dystocia is the failure to deliver the shoulders with gentle downward traction after the head is out — the head fits, and the shoulders do not. In macrosomic infants of diabetic mothers fat is deposited disproportionately at the shoulder girdle. Two cautions keep this honest: the HAPO study found strong, continuous associations between maternal glucose (even below diabetic levels) and birth weight, with no obvious threshold at which risk rises, and more than half of shoulder dystocias involve babies of normal birth weight, so the complication stays unpredictable.

One further fact stops this being taught too confidently: size raises the risk steadily rather than switching it on. Shoulder dystocia complicates about 5% to 9% of deliveries of infants weighing 4,000 to 4,500 g and "approximately 14% to 23% for infants weighing more than 4,500 g." GDM raises the risk; it does not guarantee the event.

03 Two screening systems, two sets of numbers, one patient

The most confusing part of GDM is not the physiology — it is that two entirely different screening protocols are in simultaneous use, and each has its own thresholds. The two-step approach begins with a 50 g nonfasting glucose challenge test with a plasma glucose at 1 hour; a positive result is 130, 135 or 140 mg/dL or above, depending on the institution's protocol. That is a screen, not a diagnosis. A positive screen is followed by a 100 g 3-hour oral glucose tolerance test, fasting this time, read against Carpenter-Coustan thresholds — fasting 95, 1-hour 180, 2-hour 155, 3-hour 140 mg/dL — and two or more abnormal values are required to diagnose.

The one-step approach, IADPSG's, gives every patient a 75 g 2-hour OGTT with thresholds of fasting 92, 1-hour 180, 2-hour 153 mg/dL, and a single abnormal value makes the diagnosis. One more wrinkle: the same 100 g 3-hour test also has an older, higher threshold set, the NDDG values of 105, 190, 165 and 145 mg/dL, likewise needing two abnormal values. A result can be "normal" by one set and "abnormal" by another, for the identical test — so the criteria set must be named with every number.

The consequence is measurable and unresolved. One-step screening identifies more cases of gestational diabetes than two-step screening — roughly twice as many in head-to-head trials — without a demonstrated improvement in health outcomes. The two diagnosis rates behind that comparison come from the Task Force's evidence report rather than from the recommendation statement, so this page states the direction and not the percentages. Neither approach is the right answer, and the honest teaching is to know both, name the owner of whichever numbers are in front of you, and follow the protocol the institution actually uses. The USPSTF, which is the fetched primary source here, sidesteps the argument: it accepts the two-step process, the one-step process and fasting plasma glucose measurement as reasonable screening strategies.

Both pathways are in current use and the USPSTF accepts either. The numbers only mean something attached to the criteria set that owns them — the same result can be normal by NDDG and abnormal by Carpenter-Coustan.

04 From diet control to medication — the ladder the whole management plan climbs

Treatment begins with what ADA 2026 treats as core therapy rather than an add-on: lifestyle change is a central part of GDM management and is enough on its own for many patients, with insulin added when it is needed to reach the glucose goals. That is the diet-first, medication-if-needed ladder stated as a guideline recommendation. The lifestyle prescription is specific — 30 minutes of moderate-intensity aerobic exercise at least 5 days a week, or a minimum of 150 minutes per week, and 3 small to moderate meals with 2 to 3 snacks daily built on whole-grain carbohydrates, lean protein and unsaturated fat, with reduced breakfast carbohydrates.

What decides whether the ladder is climbed is a set of three numbers, and ADA 2026 owns them: ADA 2026 Recommendation 15.8 (grade B) sets fasting plasma glucose below 95 mg/dL and either 1-hour postprandial below 140 mg/dL or 2-hour postprandial below 120 mg/dL. ADA writes these with strict less-than operators, not as "140 or less" the way some secondary sources render them — the difference decides whether a patient at exactly 140 is at target. A patient whose home log sits above target is no longer diet-controlled — she needs a drug.

Which drug is not a close call. ADA 2026 names insulin the preferred drug for GDM, and the disorder-side reason is a placental one — insulin does not cross the placenta. The contrast is explicit in the same guideline: ADA advises against metformin and glyburide — alone or together — as first-line agents in pregnancy, because both cross the placenta to the fetus and may not bring glucose to target on their own. An agent that crosses reaches a fetus whose own pancreas is already over-secreting insulin. Regimen shape follows the targets: a basal component for the fasting number and a short-acting component for the postprandial ones — and because the driver is placental, the requirement rises through gestation and then falls abruptly once the placenta is delivered.

The escalation ladder. Diet and activity are treatment, not preparation for treatment; the three ADA 2026 numbers decide when a patient moves from diet control to medication; and delivery of the placenta reverses the whole mechanism within hours.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

BMI over 25 — or over 23 in Asian Americans; obesity carries a 4- to 12-fold increased macrosomia risk through insulin resistance and hyperinsulinemia (modifiable, but the lever works before pregnancy) modifiable Physical inactivity — the sourced prescription is 150 minutes of moderate activity weekly, and it is both prevention and treatment modifiable Prior gestational diabetes, or a prior macrosomic infant weighing 4,000 g or more Family history of diabetes in a first-degree relative Higher-risk race or ethnicity — African American, Latino/Hispanic, Native American, Asian American (including South and East Asian) and Pacific Islander Increased maternal age Polycystic ovary syndrome Hemoglobin A1C above 5.7% — a risk factor only; no fetched source gives an A1C threshold that diagnoses GDM Hypertension, HDL below 35 mg/dL, or triglycerides above 250 mg/dL modifiable Factors that stack with GDM for macrosomia specifically — multiparity (parity above 3) and postterm pregnancy beyond 42 weeks

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

No symptoms at all — this is the headline finding early Expected
Why: Gestational diabetes often produces no symptoms at all. The practical consequence runs through the whole page: screening, not symptom review, finds GDM, and adherence to monitoring cannot be guided by how the patient feels.
Increased thirst and urinating more often, when anything is felt at all early Expected
Why: Osmotic diuresis from glycosuria. They are described as mild when they occur at all. They warrant a glucose check rather than reassurance — but their absence means nothing.
Fasting or postprandial values persistently above the ADA 2026 targets on the home log Hold & notify
Why: The maternal pancreas is not compensating for rising placental hormone output. This is the trigger to escalate from diet control to medication — the single most consequential finding a nurse reviews at a prenatal visit.
Insulin requirement rising visit after visit in a patient already on insulin late Expected
Why: Expected, not alarming: placental mass grows and so does hormone-driven resistance, so dosing is "individualized" and recalculated rather than fixed. Teaching this in advance prevents the patient reading a dose increase as failure.
Fundal height greater than dates, or a clinically large fetus Hold & notify
Why: Macrosomia from fetal hyperinsulinemia. It prompts an ultrasound estimated fetal weight and a delivery-planning conversation — while remembering that clinical methods such as abdominal palpation are "similarly unreliable," with maternal obesity complicating the estimate further.
New or worsening hypertension, headache, visual change, or right-upper-quadrant pain Report immediately
Why: GDM raises preeclampsia risk substantially — 18% untreated, falling to 12% with treatment. These are the preeclampsia severe-feature cues, which are owned in full by the preeclampsia page.
Decreased fetal movement Report immediately
Why: Teaching a patient to monitor fetal movements is one of three duties the source names for nurses and diabetes educators, alongside logging blood sugars and recognizing symptoms of concern. It is on the list because reduced movement is actionable — so it is reported, not observed and reassessed later.
Slow delivery of the fetal head or chin, and the turtle sign, at delivery Report immediately
Why: Impending shoulder dystocia: the shoulders have failed to negotiate the pelvis. "The most common findings include slow delivery of the fetal head or chin and the turtle sign" — enough to call the team.
Failure to deliver the shoulders with gentle downward traction after the head is out Report immediately
Why: The definition of shoulder dystocia itself — "an obstetric emergency that can complicate vaginal delivery." Incidence climbs with weight: about 1% under 4,000 g, 5–9% at 4,000–4,500 g, and 14–23% above 4,500 g.
Newborn jitteriness, tremors, poor suck or feeding difficulty Report immediately
Why: Neonatal hypoglycemia: "clamping the umbilical cord at birth abruptly terminates this continuous glucose supply," while fetal insulin remains high. These signs are late and nonspecific — which is why the newborn is screened on a clock rather than watched for symptoms.
Newborn weak or high-pitched cry, sweating, hypothermia, irritability, lethargy or hypotonia Report immediately
Why: The same hypoglycemia, further along. The full sourced list also includes seizures, coma, apnea, grunting and tachypnea — the reason the threshold for acting on a low newborn glucose is not a judgement call.
Newborn who is large for gestational age, or with disproportionate fat at the shoulders Hold & notify
Why: The macrosomic phenotype of a diabetic pregnancy — infants of diabetic mothers "commonly develop fetal hyperinsulinism," which drives overgrowth and predisposes them to hypoglycemia after birth. It identifies an infant who needs glucose screening by protocol regardless of how well he appears.

Diagnostics

Test In this disorder Normal
50 g glucose challenge test (two-step, step 1) The patient does not fast for this one, and a positive result is not a diagnosis — it is the trigger for the 3-hour test. Three cut-offs are in simultaneous use and the sources present them as alternatives, not as a progression; teach all three and use the local protocol Plasma glucose at 1 hour; positive at 130, 135 or 140 mg/dL or above, depending on the institution's protocol USPSTF 2021 (two-step process, 130–140 mg/dL); StatPearls (the three cut-offs) —
100 g 3-hour OGTT (two-step, step 2) Fasting test. Because two threshold sets exist for one test, a value can be normal by NDDG and abnormal by Carpenter-Coustan — always name the criteria set with the number Carpenter-Coustan: fasting 95, 1-hour 180, 2-hour 155, 3-hour 140 mg/dL. Two or more abnormal values diagnose GDM Carpenter-Coustan and NDDG thresholds as printed in USPSTF 2021, Table 2 Older NDDG thresholds for the identical test are higher — 105 / 190 / 165 / 145 mg/dL, also requiring two abnormal values
75 g 2-hour OGTT (one-step) The exam contrast in one line: one step, 75 g, one abnormal value; two step, 50 g screen then 100 g test, two abnormal values. One-step screening identifies more cases than two-step, without a demonstrated improvement in health outcomes — a direction the Task Force states, and percentages it leaves to its evidence report IADPSG: fasting 92, 1-hour 180, 2-hour 153 mg/dL. A single abnormal value diagnoses GDM IADPSG thresholds as printed in USPSTF 2021, Table 2 —
Screening timing An I statement is not a recommendation against early screening in a high-risk patient — but it is also not a recommendation for it. ADA 2026 describes 24–28 weeks as the usual window for diagnosing and treating GDM, and says a benefit from treating everyone before then has not been shown Screen at 24 weeks of gestation or after — Grade B. Before 24 weeks the Task Force issued an I statement: evidence is insufficient to assess the balance of benefits and harms USPSTF, 10 August 2021 (primary); ADA 2026 Section 15 —
Home self-monitored blood glucose These are the numbers that decide diet control versus medication. ADA writes under 140 at one hour — use ADA's operators. Self-monitoring is the first element of treatment, not surveillance of it Fasting under 95 mg/dL, and either 1-hour postprandial under 140 or 2-hour postprandial under 120 mg/dL ADA 2026, Recommendation 15.8 (grade B) —
Hemoglobin A1C ADA 2026 notes that A1C runs slightly lower in pregnancy, with or without diabetes, because red blood cells turn over faster. NIDDK states that the A1C test should not be used to diagnose gestational diabetes — do not import the nonpregnant threshold A1C above 5.7% is a risk factor for GDM, not a diagnostic test for it. In pregnancy generally, ADA 2026 sets an ideal A1C goal of below 6% (42 mmol/mol) when that is reachable without significant hypoglycemia, relaxed to below 7% (53 mmol/mol) where needed to prevent hypoglycemia ADA 2026, Recommendation 15.9 —
Ultrasound estimated fetal weight Macrosomia is "typically defined by an absolute birth weight," so it is confirmed at birth; before delivery, ultrasound "has limited accuracy, with errors increasing as fetal weight rises," and clinical methods are "similarly unreliable" — teach the limitation with the test, never the number alone Raises suspicion of macrosomia — but sensitivity is only 33% to 44% for birth weights above 4,500 g StatPearls —
Newborn blood glucose screening The screening list includes the infant of a diabetic mother, large for gestational age, premature or post-term delivery, perinatal stress and maternal preeclampsia. There is no universally accepted definition of neonatal hypoglycemia and recommendations on the intervention threshold vary — state the number with its owner and follow the unit protocol. On timing, British (BAPM), European (EFCNI) and Australian guidelines offer the first feed within the first hour and screen asymptomatic at-risk newborns just before the second feed (in practice no later than 2 to 4 hours after birth), then before feeds, with feeds every 2 to 3 hours (as summarised in a 2023 review of guidelines) Screened by protocol, not by symptoms. Target above 50 mg/dL in the first 48 hours of life and above 60 mg/dL thereafter, for at-risk infants without a suspected congenital disorder Pediatric Endocrine Society, as reported by StatPearls —
Postpartum reclassification Then lifelong screening every 1 to 3 years for type 2 diabetes or prediabetes. This appointment is the single most skipped and most consequential one on the page — after GDM "you will be at higher risk of developing type 2 diabetes later" (MedlinePlus). Glucose monitoring 24 to 72 hours after delivery, then a formal 75 g 2-hour OGTT at 4 to 12 weeks postpartum using nonpregnancy criteria ADA 2026, Recommendations 15.30 and 15.31 (both grade B) —

Complications

Warning: Shoulder dystocia and birth trauma Report immediately
Failure to deliver the shoulders with gentle downward traction after the head is out. Incidence by birth weight: about 1% under 4,000 g, 5–9% at 4,000–4,500 g, 14–23% above 4,500 g. Heralding cue: the turtle sign.
Fetal complications include "brachial plexus injuries, fractures of the clavicle and humerus, fetal hypoxia, and death." Plexus injuries are upper C5-C6 (Erb palsy), lower C8-T1 (Klumpke palsy) or total plexopathies, and children with obstetric plexopathies "have a generally good outcome with conservative management and observation, though some may have permanent impairments." "Maternal complications include third- or fourth-degree tears or postpartum hemorrhage." After one dystocia the mother has "a 6- to 30-fold increased risk of shoulder dystocia recurrence" with any later vaginal delivery, which is why the event is told to her plainly. Symphysis pubis separation and a transient neuralgia are complications linked to the McRoberts maneuver itself.
Warning: Neonatal hypoglycemia Report immediately
Occurs because "clamping the umbilical cord at birth abruptly terminates this continuous glucose supply" while fetal insulin is still high. The cue is the clock, not a symptom — the classic signs are late and nonspecific.
Presentation ranges from jitteriness, poor suck, weak or high-pitched cry, sweating, hypothermia, irritability and hypotonia through to lethargy, stupor, seizures, apnea and coma. Treatment starts at the breast or bottle, not with a line: increase feeding frequency and give dextrose gel 200 mg/kg massaged into the buccal mucosa; intravenous dextrose is the escalation, and an infant receiving it needs close monitoring with frequent blood glucose checks. The companion neonatal problems from the same mechanism are polycythemia, hyperbilirubinemia, hypocalcemia, hypomagnesemia, respiratory distress syndrome and increased NICU admission.
Warning: Preeclampsia — and the number that justifies treating GDM at all Report immediately
GDM raises the risk of preeclampsia (USPSTF). Heralding cues: rising blood pressure, headache, visual change, right-upper-quadrant pain.
This is the single best argument the sources supply for treating a condition the patient cannot feel. The preeclampsia page owns the severe-feature list and the magnesium toxicity ladder — cross-link, do not restate them here. One boundary must be held: a GDM diagnosis does not put a patient on low-dose aspirin prophylaxis. ADA 2026 Recommendation 15.23 names type 1 or type 2 diabetes for aspirin 100–150 mg daily from 12 to 16 weeks, and the USPSTF high-risk list likewise names pregestational diabetes. The association is real; the aspirin conclusion is not.
Caution: Macrosomia and its maternal cost
Postpartum hemorrhage (named the "leading cause of maternal mortality"), perineal trauma and lacerations, prolonged second stage, and cesarean delivery with its morbidity.
A large baby plus a prolonged second stage is the classic setup for uterine atony — the postpartum-hemorrhage page owns the 4 Ts framework; this page supplies the risk factor and links. Delivery timing and mode are planned with the obstetric provider. Scheduled cesarean for suspected macrosomia is often recommended above an estimated 5,000 g in nondiabetic and 4,500 g in diabetic patients, though "this approach remains controversial due to the lack of conclusive evidence from randomized trials."
Caution: Lifelong risk — for two people
After GDM "you will be at higher risk of developing type 2 diabetes later," and "Your baby will be at risk for obesity and type 2 diabetes later in life" (MedlinePlus).
The reason this belongs under complications rather than prognosis is that it is preventable and quantified: early intervention reduces progression to type 2 diabetes at 10 years by 35% to 40%. ADA 2026 adds two levers — it recommends breastfeeding after GDM, partly because it lowers the mother's later risk of type 2 diabetes (Rec 15.28), and it calls for intensive lifestyle intervention and/or metformin for those with overweight or obesity and prediabetes after GDM (Rec 15.32, grade A). Framing matters: the child's risk is taught as a reason for family-wide activity and nutrition, never as blame.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Insulins First-line High-alert
Endocrine

The preferred pharmacologic agent in gestational diabetes, and the reason is placental: insulin does not cross to the fetus. ADA 2026 states it plainly — insulin is the preferred drug for GDM — and the mechanism makes the preference obvious. Everything that crosses the placenta reaches a fetus whose own pancreas is already over-secreting insulin because of maternal glucose it cannot refuse; an agent that stays on the maternal side lowers maternal glucose without adding a fetal drug exposure. The regimen has a shape dictated by the targets: a basal component for the fasting number, which is placental-resistance driven and worst in the morning, and a short-acting component for the 1- and 2-hour postprandial numbers. Two disorder-side facts change nursing practice. First, the requirement climbs through gestation because placental hormone output rises with placental mass, so dosing is recalculated rather than fixed, and a dose increase is expected physiology rather than patient failure. Second, the requirement falls the moment the placenta is delivered — ADA 2026 advises reassessing and adjusting insulin after delivery because insulin resistance drops sharply right after birth. Units, titration algorithms, onset and duration profiles and hypoglycemia treatment belong to the class page.
Oral Antidiabetics
Endocrine · metformin

On this page the class is taught mainly by its limits, and the limit is a guideline recommendation rather than an opinion. ADA 2026 advises that metformin and glyburide — alone or together — not be used as first-line agents for diabetes in pregnancy, because both cross the placenta to the fetus and may not bring glucose to target on their own; it does not recommend other oral or noninsulin injectable glucose-lowering drugs because they lack long-term safety data. That crossing is the exact property insulin lacks, which is the whole comparison. Doses and titration belong to the class page. One separate rule sits here too: metformin taken for polycystic ovary syndrome or to induce ovulation is stopped by the end of the first trimester (ADA 2026, Rec 15.22, grade A).

Beyond medications

  • Medical nutrition therapy is treatment, not preparation for treatment. ADA 2026 is explicit that lifestyle change is core GDM treatment and is enough on its own for many patients. The sourced pattern is 3 small to moderate meals plus 2 to 3 snacks daily, built on whole-grain carbohydrates, lean proteins and unsaturated fats, with reduced breakfast carbohydrates — and delivered with early registered-dietitian involvement, which the macrosomia literature names specifically.
  • The exercise prescription has numbers: 30 minutes of moderate-intensity aerobic exercise at least 5 days a week, or a minimum of 150 minutes per week. It is the same figure across two independent sources, and it is both treatment during pregnancy and prevention before the next one.
  • Gestational weight gain is targeted by pre-pregnancy BMI — and weight loss is not the goal. The Institute of Medicine ranges, as reported by StatPearls, run from 28 to 40 lb (12 to 18 kg) at a BMI under 18.5 down to 11 to 20 lb (5 to 9 kg) at a BMI above 30 — and the lower bound is a gain, not a loss. During pregnancy the rule is to avoid weight loss and gain the amount appropriate to pre-pregnancy BMI. The weight lever belongs before conception: losing excess weight while planning a pregnancy, not while carrying one.
  • Delivery timing and mode are planned by clinical indicators, with the obstetric provider — the sources behind this page state no fixed week-by-class rule of their own. For suspected macrosomia, scheduled cesarean is "often recommended for suspected birth weights above 5,000 g in women without diabetes and 4,500 g in women with diabetes," but the approach "remains controversial due to the lack of conclusive evidence from randomized trials" — so vaginal delivery with individualized counseling remains common.
  • Shoulder dystocia is managed by maneuver — and one maneuver is forbidden. "Management includes calling for help, stopping maternal pushing, first-line McRoberts maneuver with or without suprapubic pressure, followed by second-line internal maneuvers." McRoberts "flexes the laboring client’s legs until their thighs touch the abdomen," and "Posterolateral suprapubic pressure is then applied to attempt to dislodge the fetal shoulder from underneath the maternal pubic bone." If that fails, the provider attempts "to deliver the posterior fetal arm or attempt to turn the fetal shoulders," and the nurse may assist the client to a hands-and-knees position. Fundal pressure must be avoided: it "only serves to impact the anterior fetal shoulder further into the pubic bone, making the shoulder dystocia worse."
  • The response starts with the call. "Once a shoulder dystocia is identified, it is important for the delivering clinician to clearly inform the other team members so they can immediately call for additional support (eg, neonatal and anesthesia clinicians)" — every second of the head-to-body interval counts, and the neonatal team should be present for an infant who may be depressed or injured. The team is built before the emergency: every unit should have a shoulder dystocia management protocol, staff should be trained, preferably through simulation, and reported training seminars cut neonatal trauma from 9.3% to 2.3%, with annual training advised.
  • Neonatal hypoglycemia is treated at the breast first. Increase feeding frequency and give dextrose gel 200 mg/kg massaged into the buccal mucosa; intravenous dextrose, with frequent glucose checks, is the escalation when feeding and gel do not hold the glucose. Breastfeeding is separately recommended after GDM for multiple benefits including a reduced maternal risk of type 2 diabetes later in life (ADA 2026, Rec 15.28).

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Review the home glucose log against the ADA 2026 targets — fasting under 95, and either 1-hour under 140 or 2-hour under 120 mg/dL — at every prenatal contact, and read the pattern rather than the worst single value.
Why: The log is the assessment in this disorder, because the patient has no symptoms to report. A pattern above target is the defined trigger to escalate from diet control to medication — the decision that most changes this pregnancy's outcome.
Name the criteria set every time you record or relay a screening number — Carpenter-Coustan, NDDG or IADPSG — and never report a glucose-challenge result as "positive" without the cut-off used.
Why: Two threshold sets exist for the identical 100 g test, and three cut-offs are in simultaneous use for the 50 g screen. A value that is normal by NDDG is abnormal by Carpenter-Coustan. An unlabelled number is not information.
Check blood pressure and ask the preeclampsia questions — headache, visual change, right-upper-quadrant pain — at every contact.
Why: Preeclampsia risk in GDM runs about 18% untreated and 12% treated, making it the commonest serious maternal complication on this page. The severe-feature list and the magnesium ladder belong to the preeclampsia page; the screening question belongs here.
Track fundal height and the fetal growth trend, and report a fundus greater than dates — while treating the ultrasound estimate as a suspicion, not a measurement.
Why: Ultrasound sensitivity for a birth weight above 4,500 g is only 33% to 44%; macrosomia is defined by birth weight, so it is confirmed only after delivery. Reporting an estimate as a fact drives decisions the evidence does not support.
Treat decreased fetal movement as a reason to escalate now, and make sure the patient has been taught what counts as decreased.
Why: The sourced duty set for nurses and diabetes educators is to teach women to "log blood sugar levels, monitor fetal movements, and recognize symptoms of concern" — three duties, of which this is the only one the patient performs without a meter. It is taught because it is actionable, and a patient who has not been told what to watch for cannot report it.
After delivery, monitor maternal glucose for 24 to 72 hours and expect the insulin requirement to fall immediately.
Why: ADA 2026: insulin resistance falls sharply right after delivery. The placenta was the driver, and it is gone. Continuing an antepartum dose into the postpartum period is a hypoglycemia risk created by the schedule, not by the patient.
Interventions & safety
Never apply fundal pressure for shoulder dystocia. The nurse's role in the maneuver set is McRoberts positioning — flexing her legs until the thighs touch the abdomen — and suprapubic pressure on request, applied posterolaterally to dislodge the anterior shoulder from under the pubic bone.
Why: Fundal pressure "only serves to impact the anterior fetal shoulder further into the pubic bone, making the shoulder dystocia worse." Fundal pressure can also heighten the risk of vaginal complications and uterine rupture. Suprapubic pressure works the other way — it tries "to dislodge the fetal shoulder from underneath the maternal pubic bone."
Call for help on a clinical trigger — the turtle sign, or shoulders that do not deliver with gentle traction — rather than after the emergency has declared itself.
Why: Management begins with "calling for help," and the delivering clinician must "clearly inform the other team members so they can immediately call for additional support" — help arrives only if it is called at the first sign.
Document the time as the shoulder dystocia protocol starts (published protocols list documentation of time with stopping pushing and getting more staff), and record the events of the delivery.
Why: Documentation of time is an early step of the published protocol, and the mother now carries a 6- to 30-fold increased risk of shoulder dystocia recurrence with any later vaginal delivery, so the event and its timing are recorded and told to her plainly.
Put every infant of a diabetic mother on the unit's newborn glucose screening protocol by definition — the Pediatric Endocrine Society's screening list (as reported by StatPearls) names the infant of a diabetic mother — regardless of how well the baby looks.
Why: Hypoglycemia follows sudden glucose withdrawal at cord clamping while fetal insulin is still high. The classic signs — jitteriness, poor feeding, lethargy — are late and nonspecific, so the schedule is the safeguard rather than the observation.
Treat a low newborn glucose with feeding and buccal dextrose gel 200 mg/kg first, escalating to intravenous dextrose when those do not hold it.
Why: Feeding addresses the actual problem — an interrupted glucose supply — and increasing feeding frequency is the preferred first intervention for an asymptomatic low glucose. Dextrose gel reduces NICU admissions for intravenous dextrose and supports continued breastfeeding; the intravenous route is the escalation, with frequent glucose checks.
State the newborn glucose target with its owner and follow the unit protocol: StatPearls, citing the Pediatric Endocrine Society, gives above 50 mg/dL in the first 48 hours and above 60 mg/dL thereafter.
Why: There is no universally accepted definition of neonatal hypoglycemia, and recommendations vary on the threshold at which intervention should begin. Naming the owner keeps the number honest, and the unit protocol is what actually governs the bedside decision.
Patient teaching
Lead with "gestational diabetes often has no symptoms." Explain that adherence to monitoring and to the 24-to-28-week screen cannot be guided by how she feels.
Why: Gestational diabetes often produces no symptoms at all, and when symptoms occur they are mild thirst and urinary frequency. A patient who feels well and stops checking has no way to know she has moved above target — which is exactly the patient whose fetus grows.
Teach the exercise and meal prescription as the treatment it is: 150 minutes of moderate activity a week, or 30 minutes at least 5 days; 3 small-to-moderate meals with 2 to 3 snacks; fewer carbohydrates at breakfast.
Why: ADA 2026 states that lifestyle change alone is enough for many patients. Framing diet and activity as the first drug, rather than as advice preceding the real treatment, is what makes diet-only control achievable.
Explain that gestational weight gain is the target and weight loss is not — and that the weight lever belongs to the time before the next pregnancy.
Why: The sourced ranges are gains at every BMI category, bottoming out at 11 to 20 lb (5 to 9 kg) above a BMI of 30 — there is no category whose target is a loss. Dieting to lose weight while pregnant is a common and well-meant error that the sources contradict directly.
If insulin is started, teach that it was chosen because it does not cross the placenta, and that a rising dose through the third trimester is expected physiology.
Why: Both facts prevent the two commonest misreadings: that insulin means she failed, and that a dose increase means she is getting worse. The placenta is growing, so the resistance is growing — the medication is tracking the pregnancy, not her effort.
Book the postpartum test before she leaves. A 75 g 2-hour OGTT at 4 to 12 weeks, then glucose testing every 1 to 3 years for life.
Why: Type 2 diabetes risk stays higher after GDM (MedlinePlus), and early intervention reduces 10-year progression by 35% to 40%. This is the appointment most often missed and the one with the largest long-term return.
Recommend breastfeeding, and frame the child's later risk as a reason for family-wide nutrition and activity rather than as blame.
Why: ADA 2026 recommends breastfeeding after GDM for multiple benefits including a reduced maternal risk of type 2 diabetes. The child's increased risk of obesity and type 2 diabetes is real, and delivering it as a shared family goal is what makes it actionable rather than shaming.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    Two clusters matter here and the patient can feel neither of them. The risk cluster: BMI 31 and a prior infant of 4,200 g are both named risk factors — obesity and a prior macrosomic infant of 4,000 g or more. The result cluster: a 1-hour challenge of 158 mg/dL is above all three cut-offs in use, and on the confirmatory 3-hour test the fasting 98 (threshold 95) and the 1-hour 192 (threshold 180) are abnormal, while the 2-hour 150 (threshold 155) and 3-hour 132 (threshold 140) are not. Four weeks later the home log shows fasting values of 104 to 112 against a target of under 95. Everything reassuring in the chart — she feels well, her blood pressure is normal, movement is normal — is true and irrelevant to the diagnosis.

  2. 2
    Analyze cues

    By Carpenter-Coustan, two abnormal values on the 100 g 3-hour test diagnose gestational diabetes — and she has exactly two. Say the criteria set out loud, because by NDDG thresholds (105 / 190 / 165 / 145) her fasting 98 and 1-hour 192 would read as one abnormal value, not two, and she would not be diagnosed at all. The same blood, a different answer. Mechanistically this is second-trimester placental hormone output — human placental lactogen primarily, with cortisol and prolactin — producing insulin resistance her beta cells cannot match. Four weeks of nutrition therapy and 150 minutes of weekly activity is the correct first treatment, and ADA 2026 says it is enough on its own for many patients. It has not been enough here. Fasting values of 104 to 112 sit persistently above the ADA 2026 target of under 95, and fasting hyperglycemia is the placental-resistance number — the one that responds least to meal timing. Her postprandial log is not clean either: most 1-hour values are at target, but the top of her range, 146 mg/dL, is above the 140 threshold — a second abnormal number, and one that would be missed by anyone reading only the fasting column. She now needs pharmacologic therapy.

  3. 3
    Prioritize

    The priority is not comfort and not reassurance; it is starting pharmacologic therapy before fetal overgrowth is established, because infants of diabetic mothers develop fetal hyperinsulinism, and GDM raises the risk of fetal macrosomia with shoulder dystocia and birth injury. Alongside that sits the ongoing preeclampsia watch, since GDM carries roughly an 18% untreated risk falling to 12% with treatment, which makes her blood pressure and symptom review a standing item rather than a formality. Third is the delivery plan, made with the obstetric provider by clinical indicators. What is explicitly not a priority: an early induction for size — induction for suspected macrosomia "has been discouraged due to the lack of clear evidence on its significance" — and low-dose aspirin. Neither is supported for this patient.

  4. 4
    Generate solutions

    Escalate to insulin, which ADA 2026 names the preferred agent for GDM, with the reason given to the patient in one sentence: it does not cross the placenta. Anticipate a basal component aimed at her fasting numbers and a short-acting component for postprandial values, with the dose recalculated as pregnancy advances rather than fixed. Anticipate that metformin or glyburide will not be offered first — ADA 2026 advises against both as first-line agents because both cross the placenta to the fetus. Plan the delivery timing and mode with the obstetric provider by clinical indicators. Arrange a growth ultrasound while stating its limits — sensitivity 33% to 44% above 4,500 g. And book the 75 g 2-hour OGTT for 4 to 12 weeks postpartum now, while she is in the room.

  5. 5
    Take action

    Start insulin teaching with the two pre-emptive messages that prevent the commonest misreadings: insulin was chosen for a placental reason, not because she failed, and the dose will rise through the third trimester because the placenta is growing. Reinforce that nutrition therapy and activity continue — insulin is added to them, not substituted for them. Confirm she can state her three targets: fasting under 95, and either 1-hour under 140 or 2-hour under 120. Teach her how to monitor fetal movements, and review the preeclampsia symptoms to report. Flag the delivery plan in the chart with its class rationale so that a colleague reading it later does not induce early for an ultrasound estimate. At delivery, the handoff must name her as an insulin-treated GDM so that the newborn goes onto the glucose protocol automatically and the team is primed for McRoberts and suprapubic pressure — never fundal pressure — if the shoulders hesitate.

  6. 6
    Evaluate

    Success antenatally looks like fasting values under 95 within a few weeks of insulin titration, a growth trend that stays off the extreme percentiles, and a blood pressure that stays normal. At delivery it looks like a prepared team rather than a lucky one. Afterwards, evaluation moves to the newborn and to her: the baby goes onto the newborn glucose screening protocol regardless of how well it looks, and a value of 38 mg/dL at 2 hours of life is below the Pediatric Endocrine Society target of above 50 mg/dL (as reported by StatPearls) — treated with more frequent feeding and buccal dextrose gel 200 mg/kg, not observed. Her own insulin is reassessed immediately after the placenta is delivered, because resistance drops sharply right after delivery, and her glucose is monitored for 24 to 72 hours. The last evaluation point is months away and is the one that matters most: did she attend the 4-to-12-week OGTT? Her type 2 diabetes risk stays higher, and early intervention cuts 10-year progression by 35% to 40%.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Prenatal clinic, then the labor and delivery unit twelve weeks later

A 29-year-old at 27 weeks, gravida 2 para 1. Pre-pregnancy BMI 31. Her first child was born at 4,200 g. She feels well and reports no symptoms. A 50 g glucose challenge test was drawn last week because of the routine 24-to-28-week screen.

Screening — 50 g nonfasting GCT at 1 hour: 158 mg/dL (above every listed cut-off of 130, 135 and 140)
Confirmatory 100 g 3-hour OGTT — fasting 98 · 1-hour 192 · 2-hour 150 · 3-hour 132 mg/dL
History — BMI 31 · prior infant 4,200 g · no personal history of diabetes · no symptoms reported
Vitals — BP 118/72 · no headache, visual change or right-upper-quadrant pain · fetal movement normal
Home log at 31 weeks, after 4 weeks of nutrition therapy and 150 min/week activity — fasting 104 to 112 mg/dL · 1-hour postprandial 128 to 146 mg/dL
Q1 Multiple choice
The 100 g 3-hour OGTT returns fasting 98, 1-hour 192, 2-hour 150, 3-hour 132 mg/dL. Which statement is correct?
  1. A. One abnormal value is present, so this does not meet criteria by any standard
  2. B. Two abnormal values are present by Carpenter-Coustan, which diagnoses gestational diabetes — and the criteria set must be named with the result
  3. C. All four values are abnormal, confirming severe gestational diabetes
  4. D. The 3-hour value of 132 is the only one that matters, and it is normal
Reveal answer & rationale
Answer: B
Carpenter-Coustan thresholds are fasting 95, 1-hour 180, 2-hour 155, 3-hour 140, and two or more abnormal values diagnose GDM. The fasting 98 and the 1-hour 192 are both abnormal; the 2-hour 150 and 3-hour 132 are not (B). Option A ignores that two values exceed their thresholds. Option C is wrong on three of four values. Option D invents a hierarchy the criteria do not contain — all four values are read against their own thresholds. The reason B insists on naming the criteria set is that the older NDDG thresholds (105 / 190 / 165 / 145) would score this same blood as only one abnormal value, and she would not be diagnosed.
Q2 Select all that apply
After four weeks of nutrition therapy and activity, her fasting values run 104 to 112 mg/dL. Which actions are appropriate? Select all that apply.
  1. A. Recognize that diet control has failed and she needs pharmacologic therapy
  2. B. Start insulin, explaining that it is preferred because it does not cross the placenta
  3. C. Start low-dose aspirin, since gestational diabetes is a high-risk factor for preeclampsia
  4. D. Continue medical nutrition therapy and activity alongside the new medication
  5. E. Reassure her that fasting values in the low 100s are acceptable in pregnancy
Reveal answer & rationale
Answer: A, B, D
Persistent values above the ADA 2026 targets define the move from diet control to pharmacologic therapy (A). Insulin is ADA 2026's preferred drug for GDM, and the disorder-side reason — it does not cross the placenta, unlike metformin and glyburide — is exactly what the patient should be told (B). Lifestyle therapy continues; ADA 2026 frames insulin as added to it, not substituted for it (D). Option C is the trap this page kills: ADA 2026 Recommendation 15.23 prescribes aspirin for type 1 or type 2 diabetes, and the USPSTF high-risk list names pregestational diabetes — a GDM diagnosis does not put a patient on aspirin. Option E contradicts the target of fasting under 95 mg/dL, and in the HAPO study the association between maternal glucose and birth weight was continuous, with no obvious threshold at which risk rose.
Q3 Put in order
The head delivers and then retracts toward the perineum; the shoulders do not deliver with gentle downward traction. Put the nurse's actions in priority order:
  1. A. Apply posterolateral suprapubic pressure when directed
  2. B. Call for help on the clinical trigger
  3. C. Document the time and the events of the delivery
  4. D. Assist with McRoberts positioning — legs flexed until the thighs touch the abdomen
Reveal answer & rationale
Correct order: B → D → A → C
The turtle sign with failure to deliver the shoulders is the clinical trigger, and management "includes calling for help" first — the delivering clinician must "clearly inform the other team members so they can immediately call for additional support" (B). McRoberts is the first maneuver, flexing the thighs to the abdomen (D). Suprapubic pressure follows, to dislodge the anterior shoulder from under the pubic bone (A). Documentation follows the care (C) — the mother now carries a 6- to 30-fold recurrence risk. The action absent from every option is the point: fundal pressure is never applied — it "only serves to impact the anterior fetal shoulder further into the pubic bone, making the shoulder dystocia worse."
Q4 Multiple choice
The newborn of this insulin-treated mother is vigorous and feeding well. Blood glucose at 2 hours of life is 38 mg/dL. The nurse should:
  1. A. Document the value and recheck in 6 hours, since the baby is asymptomatic
  2. B. Increase feeding frequency and give buccal dextrose gel 200 mg/kg, then recheck
  3. C. Start an intravenous dextrose infusion immediately as the first intervention
  4. D. Take no action, because 38 mg/dL is within the Pediatric Endocrine Society target
Reveal answer & rationale
Answer: B
38 mg/dL is below the Pediatric Endocrine Society target of above 50 mg/dL in the first 48 hours (as reported by StatPearls), and treatment begins with the mechanism — an interrupted glucose supply — so the first steps are increased feeding frequency and dextrose gel 200 mg/kg massaged into the buccal mucosa (B). Option A relies on symptoms, and the classic signs of neonatal hypoglycemia are late and nonspecific, which is precisely why screening runs on a clock. Option C escalates past the first-line treatment: increasing feeding frequency is the preferred initial intervention for an asymptomatic infant, and dextrose gel reduces NICU admissions for intravenous dextrose. Option D misreads the PES framework — its target is above 50 mg/dL, so 38 mg/dL is below it and requires action.
Q5 Multiple choice
At the postpartum visit, which statement by the patient shows that teaching has been effective?
  1. A. "My diabetes is gone now that the baby is born, so I don't need any more testing."
  2. B. "I'll have the two-hour glucose tolerance test between four and twelve weeks, and then get tested every one to three years."
  3. C. "I should keep taking the same insulin dose for a few months to be safe."
  4. D. "I'll avoid breastfeeding because it could affect my blood sugar."
Reveal answer & rationale
Answer: B
ADA 2026 recommends screening with a 75 g OGTT at 4 to 12 weeks postpartum using nonpregnancy criteria, then lifelong screening every 1 to 3 years (B). Option A is the belief that makes this the most-missed appointment in the disorder — her risk of type 2 diabetes later is higher (MedlinePlus), and early intervention cuts 10-year progression by 35% to 40%. Option C is dangerous: insulin resistance drops sharply right after delivery once the placenta is gone, so the antepartum dose is a hypoglycemia risk. Option D inverts the recommendation — breastfeeding is recommended after GDM, including for a reduced maternal risk of type 2 diabetes later in life.

Common questions

What causes gestational diabetes?
Common causes and risk factors include bmi over 25 — or over 23 in asian americans; obesity carries a 4- to 12-fold increased macrosomia risk through insulin resistance and hyperinsulinemia (modifiable, but the lever works before pregnancy), physical inactivity — the sourced prescription is 150 minutes of moderate activity weekly, and it is both prevention and treatment, prior gestational diabetes, or a prior macrosomic infant weighing 4,000 g or more, family history of diabetes in a first-degree relative, higher-risk race or ethnicity — african american, latino/hispanic, native american, asian american (including south and east asian) and pacific islander, and others.
What are the early signs of gestational diabetes?
Early findings include No symptoms at all — this is the headline finding, Increased thirst and urinating more often, when anything is felt at all.
Which findings should a nurse report immediately in gestational diabetes?
Report immediately: New or worsening hypertension, headache, visual change, or right-upper-quadrant pain, Decreased fetal movement, Slow delivery of the fetal head or chin, and the turtle sign, at delivery, Failure to deliver the shoulders with gentle downward traction after the head is out, Newborn jitteriness, tremors, poor suck or feeding difficulty, and others. These signal deterioration that needs rapid intervention.
Why is insulin used instead of a pill, when the patient is not a type 1 diabetic?
Because of where the drug goes. Insulin does not cross the placenta; metformin and glyburide both do. ADA 2026 names insulin the preferred drug for GDM and advises against metformin and glyburide, alone or together, as first-line agents in pregnancy — both cross the placenta to the fetus and may not bring glucose to target on their own. The mechanism makes the preference obvious: the fetus of a hyperglycemic mother already has an over-secreting pancreas, so an agent that crosses adds a drug exposure to a fetus that does not need one.
One-step or two-step — which screening approach is correct?
Neither, and that is the honest answer. The one-step 75 g 2-hour OGTT (IADPSG: 92 / 180 / 153, one abnormal value diagnoses) identifies more cases than the two-step 50 g nonfasting screen followed by a 100 g 3-hour test (Carpenter-Coustan: 95 / 180 / 155 / 140, two abnormal values diagnose) — roughly twice as many — without a demonstrated improvement in health outcomes. The USPSTF, the fetched primary source, accepts the two-step process, the one-step process and fasting plasma glucose measurement alike. What matters clinically is that the criteria set is named with every number, because a value can be normal by the older NDDG thresholds (105 / 190 / 165 / 145) and abnormal by Carpenter-Coustan on the identical test.
Does gestational diabetes cause birth defects?
No — and the distinction is worth making carefully, because the fear is common. Congenital anomaly risk is tied to high blood glucose at the beginning of a pregnancy, which is a pregestational diabetes problem: organogenesis is finished long before GDM appears. Gestational diabetes by definition develops in the second half of pregnancy, after physiologic insulin resistance rises in the second trimester, which is why the screen sits at 24 to 28 weeks. GDM's fetal signature is overgrowth, not malformation — macrosomia, sometimes with disproportionate fat at the shoulders, shoulder dystocia risk, and neonatal hypoglycemia at cord clamp. The corollary matters for the next pregnancy: a woman with a GDM history who becomes pregnant again benefits most from glucose control before and around conception, not only from the 24-week screen.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.